GE
MACK icon

General Electric’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

General Electric’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-5,610
Closed -$222K – 225
2014
Q1 		$222K Hold
5,610
– – ﹤0.01% 205
2013
Q4 		$235K Sell
5,610
-89
-2% -$2.58K ﹤0.01% 208
2013
Q3 		$170K Buy
5,699
+211
+4% +$7.38K ﹤0.01% 214
2013
Q2 		$291K Buy
+5,488
New +$241K ﹤0.01% 213

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

General Electric's MACK Position: Q2 2014 in Review

General Electric sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2014, closing a stake of 5,610 shares — an estimated $222K sold.

General Electric first reported a position in MACK in Q2 2013 and held it in 4 quarters. The position peaked at $291K in Q2 2013. 121 funds tracked by Wall St. Rank hold MACK as of Q2 2014.

  • General Electric reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • General Electric sold 5,610 Merrimack Pharmaceuticals, Inc. shares in Q2 2014, an estimated $222K.
  • General Electric first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 4 quarters.
  • General Electric's Merrimack Pharmaceuticals, Inc. position peaked at $291K in Q2 2013.
  • 121 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2014.

Based on General Electric's 13F filing for Q2 2014, filed 6 Aug 2014.